These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 31549414)
1. Modification of the cyclopropyl moiety of abacavir provides insight into the structure activity relationship between HLA-B*57:01 binding and T-cell activation. Thomson PJ; Illing PT; Farrell J; Alhaidari M; Bell CC; Berry N; O'Neill PM; Purcell AW; Park KB; Naisbitt DJ Allergy; 2020 Mar; 75(3):636-647. PubMed ID: 31549414 [TBL] [Abstract][Full Text] [Related]
2. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation. Naisbitt DJ; Yang EL; Alhaidari M; Berry NG; Lawrenson AS; Farrell J; Martin P; Strebel K; Owen A; Pye M; French NS; Clarke SE; O'Neill PM; Park BK AIDS; 2015 Nov; 29(18):2385-95. PubMed ID: 26372480 [TBL] [Abstract][Full Text] [Related]
3. T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms. Bell CC; Faulkner L; Martinsson K; Farrell J; Alfirevic A; Tugwood J; Pirmohamed M; Naisbitt DJ; Park BK Chem Res Toxicol; 2013 May; 26(5):759-66. PubMed ID: 23541086 [TBL] [Abstract][Full Text] [Related]
5. The Role of Conformational Dynamics in Abacavir-Induced Hypersensitivity Syndrome. Fodor J; Riley BT; Kass I; Buckle AM; Borg NA Sci Rep; 2019 Jul; 9(1):10523. PubMed ID: 31324847 [TBL] [Abstract][Full Text] [Related]
6. Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients. Faridi RM; Patel S; Dharmani-Khan P; Gill J; Berka N; Khan FM Microbiol Immunol; 2020 Mar; 64(3):210-218. PubMed ID: 31876322 [TBL] [Abstract][Full Text] [Related]
7. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. Norcross MA; Luo S; Lu L; Boyne MT; Gomarteli M; Rennels AD; Woodcock J; Margulies DH; McMurtrey C; Vernon S; Hildebrand WH; Buchli R AIDS; 2012 Jul; 26(11):F21-9. PubMed ID: 22617051 [TBL] [Abstract][Full Text] [Related]
8. Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity. Metushi IG; Wriston A; Banerjee P; Gohlke BO; English AM; Lucas A; Moore C; Sidney J; Buus S; Ostrov DA; Mallal S; Phillips E; Shabanowitz J; Hunt DF; Preissner R; Peters B PLoS One; 2015; 10(5):e0124878. PubMed ID: 26024233 [TBL] [Abstract][Full Text] [Related]
9. Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire. Illing PT; van Hateren A; Darley R; Croft NP; Mifsud NA; King S; Kostenko L; Bharadwaj M; McCluskey J; Elliott T; Purcell AW Front Immunol; 2021; 12():672737. PubMed ID: 34093574 [TBL] [Abstract][Full Text] [Related]
10. Abacavir induced T cell reactivity from drug naïve individuals shares features of allo-immune responses. Adam J; Wuillemin N; Watkins S; Jamin H; Eriksson KK; Villiger P; Fontana S; Pichler WJ; Yerly D PLoS One; 2014; 9(4):e95339. PubMed ID: 24751900 [TBL] [Abstract][Full Text] [Related]
11. Drug-induced alloreactivity: A new paradigm for allorecognition. D'Orsogna LJ; Almeida CM; van Miert P; Zoet YM; Anholts JDH; Chopra A; Watson M; Witt C; John M; Claas FHJ Am J Transplant; 2019 Sep; 19(9):2606-2613. PubMed ID: 31125485 [TBL] [Abstract][Full Text] [Related]
12. Critical assessment of approaches for molecular docking to elucidate associations of HLA alleles with adverse drug reactions. Ramsbottom KA; Carr DF; Jones AR; Rigden DJ Mol Immunol; 2018 Sep; 101():488-499. PubMed ID: 30125869 [TBL] [Abstract][Full Text] [Related]
13. Abacavir-reactive memory T cells are present in drug naïve individuals. Lucas A; Lucas M; Strhyn A; Keane NM; McKinnon E; Pavlos R; Moran EM; Meyer-Pannwitt V; Gaudieri S; D'Orsogna L; Kalams S; Ostrov DA; Buus S; Peters B; Mallal S; Phillips E PLoS One; 2015; 10(2):e0117160. PubMed ID: 25674793 [TBL] [Abstract][Full Text] [Related]
14. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Chessman D; Kostenko L; Lethborg T; Purcell AW; Williamson NA; Chen Z; Kjer-Nielsen L; Mifsud NA; Tait BD; Holdsworth R; Almeida CA; Nolan D; Macdonald WA; Archbold JK; Kellerher AD; Marriott D; Mallal S; Bharadwaj M; Rossjohn J; McCluskey J Immunity; 2008 Jun; 28(6):822-32. PubMed ID: 18549801 [TBL] [Abstract][Full Text] [Related]
15. Structural Elements Recognized by Abacavir-Induced T Cells. Yerly D; Pompeu YA; Schutte RJ; Eriksson KK; Strhyn A; Bracey AW; Buus S; Ostrov DA Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28686208 [TBL] [Abstract][Full Text] [Related]
16. The PD1 inhibitory pathway and mature dendritic cells contribute to abacavir hypersensitivity in human leukocyte antigen transgenic PD1 knockout mice. Song B; Aoki S; Liu C; Susukida T; Kuwahara S; Ito K Toxicology; 2021 Nov; 463():152971. PubMed ID: 34606953 [TBL] [Abstract][Full Text] [Related]
17. Abacavir adverse reactions related with HLA-B*57: 01 haplotype in a large cohort of patients infected with HIV. Quiros-Roldan E; Gardini G; Properzi M; Ferraresi A; Carella G; Marchi A; Malagoli A; Focà E; Castelli F Pharmacogenet Genomics; 2020 Oct; 30(8):167-174. PubMed ID: 32453265 [TBL] [Abstract][Full Text] [Related]
18. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Martin AM; Nolan D; Gaudieri S; Almeida CA; Nolan R; James I; Carvalho F; Phillips E; Christiansen FT; Purcell AW; McCluskey J; Mallal S Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4180-5. PubMed ID: 15024131 [TBL] [Abstract][Full Text] [Related]
19. Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration. Phillips EJ; Mallal SA J Clin Invest; 2018 Jul; 128(7):2746-2749. PubMed ID: 29781810 [TBL] [Abstract][Full Text] [Related]
20. Detection of Abacavir-Induced Structural Alterations in Human Leukocyte Antigen-B*57 : 01 Using Phage Display. Shirayanagi T; Aoki S; Fujimori S; Watanabe K; Aida T; Hirasawa M; Kumagai K; Hoshino T; Ito K Biol Pharm Bull; 2020; 43(6):1007-1015. PubMed ID: 32475910 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]